Javier García-Corbacho

8PUBLICATIONS
75CO-AUTHORS
Innate immunityMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Pharmaceutical delivery technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Apr 26, 2024
First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study.

Duncan A Wheatley, Rossana Berardi, Miguel A Climent Duran

|Oct 06, 2022
SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA.

Aleix Prat, Luis Paz-Ares, Manel Juan

|Jun 10, 2022
Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer.

R C Coombes, P D Badman, J P Lozano-Kuehne

|Mar 05, 2022
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors.

Atish D Choudhury, Celestia S Higano, Johann S de Bono

|Feb 15, 2022
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.

Valentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau

|Jun 04, 2021
Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies.

Melissa Johnson, Anthony El-Khoueiry, Navid Hafez

Pageof 2